Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
NCT00672191 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the body's immune response to HIV-1; and, to determine if after stopping anti-HIV drugs, immunotherapy can control the HIV-1 virus.
Conditions Studied
Interventions
- BIOLOGICAL AGS-004
Study Locations (12)
Ontario
- Hamilton Health Sciences - McMaster University Medical Centre — Hamilton
- The Ottawa Hospital — Ottawa
- Sunnybrook Health Sciences Center — Toronto
- Maple Leaf Clinic — Toronto
- UHN — Toronto
Quebec
- Clinique medicale l'Actuel — Montreal
- Clinique Medical du Quartier Latin — Montreal
- Montreal Chest Institute — Montreal
- CHUM — Montreal
Pennsylvania
- Practice Comprehensive Care Practice Div of Onfectious Disease & HIV Med — Philadelphia
Alberta
- Southern Alberta Clinic — Calgary
British Columbia
- Providence Health Care Society / The University of British Columbia / BC Centre for Excellence in HIV/AIDS — Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00672191
The ClinicalTrials.gov registry entry for NCT00672191 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Argos Therapeutics, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention — of which AGS-004 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00672191 reports 12 study locations spanning 5 distinct geographic areas — top geographies include Ontario, Quebec, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00672191 about?
NCT00672191 is a clinical study titled "Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV". The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the body's immune response to HIV-1; and, to determine if after stopping a...
What is the current status of trial NCT00672191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2008-02. Estimated completion is 2011-11.
What conditions does trial NCT00672191 study?
This clinical trial studies the following conditions: HIV Infections. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00672191?
The interventions under investigation include: AGS-004 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00672191?
This trial is sponsored by Argos Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00672191 being conducted?
This trial has 12 study locations across Pennsylvania, Alberta, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.